Author + information
- Valay Parikh,
- Madhav Lavu,
- Venkat Lakshmi Kishan Vuddanda,
- Mohammad Jazayeri,
- Vidhya Reddy,
- Bhavya Yarlagadda,
- Himabindu Korra,
- Rakesh Venkata,
- Sudharani Bommana,
- Donita Atkins,
- Madhu Reddy and
- Dhanunjaya Lakkireddy
Background: Safety of peri-procedural use of novel oral anticoagulation agents (NOACs) during cardiac device implantation has been suggested in small observational studies. Larger data affirming its safety is lacking.
Methods: We performed a multicenter evaluation of safety of uninterrupted anticoagulation with NOACs during cardiac device implantation procedures. 965 consecutive patients from 3 centers were included in the study. Baseline demographics and complication rates were collected.
Results: 553 (57%) patients were on warfarin and 412 (43%) patients were on NOACs. Out of these, 511 (53%) had new device implantation, 285 (29.5%) had generator change and 169 (17.6%) had device upgrade. Mean INR in warfarin group was 2.07 ± 0.76. NOAC group included 93 (22.6 %) patients on dabigatran, 198 (48.2 %) patients on rivaroxaban, 119 (28.9%) patients on apixaban and 1 (0.2%) patient was on edoxaban. NOACs were continued un-interrupted in majority and resumed within 24 hours of the procedure. There were no significant differences in the total bleeding (5.1 % vs 6.6%; p=0.33) or non-minor bleeding (2.3% vs 2.4%; p=0.79) rates between both the groups. Results were consistent after adjusting for other variables using multivariate logistic regression analysis. There were no thromboembolic events or deaths in any of the groups.
Conclusions: Peri-procedural use of novel oral anticoagulation agents during cardiac device implantation appears to be safe.
Room 146 A
Saturday, March 18, 2017, 9:04 a.m.-9:14 a.m.
Session Title: Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review
Abstract Category: 5. Arrhythmias and Clinical EP: Devices
Presentation Number: 901-12
- 2017 American College of Cardiology Foundation